Peptide Shots for Weight Loss: What the Evidence Actually Shows

“Peptide shots for weight loss” is a confusing search because it bundles two very different worlds. On one side are the peptides with genuine randomized-trial evidence — and here is the key fact most peptide marketing skips: semaglutide and tirzepatide are peptides. The GLP-1 “weight loss shots” that produce 15–21% body-weight loss are peptide injections^[1][2][3]. On the other side are “research peptides” sold online — BPC-157, AOD-9604, CJC-1295/ipamorelin, MOTS-c — marketed for fat loss with no Phase 3 human weight-loss trial behind any of them. This article sorts the peptide shots by what the human evidence actually shows.

The honest summary

• The GLP-1s are peptides — and they are the peptides that work. Semaglutide is a 31-amino-acid GLP-1 analogue^[1]; tirzepatide is a 39-amino-acid dual GIP/GLP-1 agonist. Their weight-loss trials are the benchmark: ~14.9% (STEP-1)^[2] and ~20.9% (SURMOUNT-1)^[3], with a head-to-head confirming tirzepatide’s edge^[7].
• Cagrilintide is the one non-GLP-1 peptide with a credible human signal. An amylin analogue, it produced ~10.8% weight loss at 26 weeks in a Lancet Phase 2 dose-finding trial^[5] — but it is being developed in combination (CagriSema), is investigational, and is not FDA-approved.
• The “research peptides” do not have the evidence. AOD-9604 lost weight in obese mice^[6] but its human obesity program was discontinued; BPC-157, CJC-1295/ipamorelin, and MOTS-c have no published Phase 3 human weight-loss RCT. These are sold as compounded or gray-market products, not approved drugs.
• Tesamorelin is FDA-approved — but not for general weight loss. Its only approved indication is reduction of excess abdominal fat in HIV-associated lipodystrophy, not obesity.
• “Peptide” is not a quality signal. The word covers both the best-evidenced obesity drugs in history and unproven research chemicals. The evidence, not the label, is what matters.

What a peptide actually is (and why it matters here)

A peptide is a short chain of amino acids — the same building blocks as proteins, just shorter. That definition is deliberately broad, which is exactly why “peptides for weight loss” is such a slippery category. Insulin is a peptide. So is semaglutide, the molecule in Wegovy and Ozempic: it is a 31-amino-acid analogue of human GLP-1, engineered for once-weekly dosing^[1]. Tirzepatide (Zepbound, Mounjaro) is a 39-amino-acid peptide that activates both the GIP and GLP-1 receptors. When someone says a “peptide shot” helped them lose weight and it was a GLP-1, that is completely consistent with the trial evidence. The problem is that the same word gets attached to research chemicals with no comparable data, borrowing credibility from the approved drugs.

Category 1 — GLP-1 peptides: the ones with trial evidence

The FDA-approved peptide injections for weight are all GLP-1-based. Semaglutide 2.4 mg (Wegovy) produced a mean ~14.9% reduction in body weight over 68 weeks in STEP-1^[2]. Tirzepatide (Zepbound) produced ~20.9% over 72 weeks in SURMOUNT-1^[3], and the SURMOUNT-5 head-to-head trial confirmed tirzepatide outperformed semaglutide directly^[7]. Liraglutide (Saxenda), an earlier daily GLP-1 peptide, produced ~8% in the SCALE trial^[4]. These are the “weight loss shots” that work — and they happen to be peptides. Compounded versions of these same peptide molecules exist from 503A pharmacies; they contain the same active ingredient but are not FDA-approved products. For the full landscape, see what are peptides for weight loss and our semaglutide and tirzepatide guides.

Category 2 — cagrilintide: the one credible non-GLP-1 peptide

Cagrilintide is a long-acting analogue of amylin, a different appetite-regulating peptide hormone. It is the only non-GLP-1 weight-loss peptide with a credible published human signal: in a Lancet Phase 2 dose-finding trial, once-weekly cagrilintide produced up to ~10.8% weight loss at 26 weeks^[5]. That is a real result — but the honest framing is that cagrilintide is investigational, not FDA-approved, and is being developed mainly in combination with semaglutide (as CagriSema) rather than as a standalone shot. Anything sold today as “cagrilintide” outside a clinical trial is not an approved product. We cover the non-GLP-1 peptide field in depth in non-GLP-1 peptides for fat loss.

Category 3 — research peptides: hype outrunning the evidence

This is where most of the “peptide shots for weight loss” marketing actually lives, and where the evidence collapses. AOD-9604, a fragment of human growth hormone, reduced weight in obese mice^[6], but its human obesity development program was discontinued and there is no Phase 2/3 human weight-loss RCT supporting the injectable products sold today. BPC-157 is a “body protection compound” peptide with no FDA approval and no human weight-loss trial; the FDA has flagged it in its compounding review. CJC-1295 / ipamorelin are growth-hormone secretagogues sold for “recomposition” with no published RCT measuring weight loss as an endpoint, making the fat-loss claim mechanistic speculation. MOTS-c is a mitochondrial-derived peptide that is research-use only. Several of these are prohibited in sport and are sold through gray-market channels where purity is unverifiable.

One more that trips people up: tesamorelin (Egrifta) is a genuinely FDA-approved peptide — but only for reduction of excess abdominal fat in HIV-associated lipodystrophy, not for general obesity. Citing its approval as evidence that “peptides work for weight loss” misrepresents a narrow indication. The pattern across Category 3 is consistent: an interesting mechanism, animal or niche data, and a marketing leap to “fat-loss shot” that the human evidence has not earned. For the oral versions of this same hype cycle, see oral peptides for weight loss: evidence vs hype.

Bottom line

If a “peptide shot for weight loss” has real randomized evidence, it is almost certainly a GLP-1 — semaglutide or tirzepatide — because those are peptides with landmark trials behind them^[2][3][7]. Cagrilintide is the one non-GLP-1 peptide with a credible human signal^[5], but it is investigational. The research peptides — BPC-157, AOD-9604, CJC-1295/ipamorelin, MOTS-c — are marketing ahead of the evidence, with no Phase 3 human weight-loss data. Choose the shot by its trial record, not by whether the word “peptide” is on the label.